clinical research

View All

TRAIL-Receptor-Agonists
TRAIL Receptor Agonists: Emerging target therapies against Cancer

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L) is a type II trans membrane protein belonging to the Tumor Necrosis Factor (TNF) superfamily that are widely expressed on the surface of Natural Killer (NK) and T cells, macrophages and dendrite cells. These pr...

Find More

HER2 Expression and its Dynamic Functional States

A research published in Nature recently identified some dynamic functional states in the breast cancer cells of HER2 breast cancer. The research postulates that women who have advanced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, are prone to acquire a HER2...

Find More

Delveinsight
Delveinsight launched novel Drug Pipeline reports

Over the past six months, DelveInsight has proven its value to their customers with its excellent deliverables. Now newly launched DelveInsight's Pipeline Reports is the answer to all looking for top notch drug development information. In the fast-paced, competitive field of clinical research, organizations must...

Find More